Bank of America Corp DE bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 1,142,539 shares of the company

Vir Biotechnology stock posted USD 238.9 million in Q2 2026 revenue, versus USD 135.88 million conse

En Yahoo Finance, obtienes cotizaciones de acciones gratuitas, noticias actualizadas, recursos de gestión de carteras, datos de mercados internacionales, interacción social y tasas hipotecarias que te ayudarán a gestionar tu vida financiera.

Engineers Gate Manager LP trimmed its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 48.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,427 shares of the company

Squarepoint Ops LLC raised its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 384.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 126,141 shares of the company

WINTON GROUP Ltd decreased its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 58.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,491 shares of the company

Former Vir executive Jason V. O’Byrne plans to sell 28,333 VIR shares for about $315K, after three prior August sales totaling over 62,000 shares.

Legal & General Group Plc bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 270,875 shares of the company

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has received an average rating of "Moderate Buy" from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recom

Bank of New York Mellon Corp bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 694,374 shares of the company